AstraZeneca: Joint Approach in Amylin Deal 'Made Sense'
After Bristol-Myers Squibb Co. announced the acquisition of Amylin Pharmaceuticals Inc. late Friday afternoon, it emerged that the deal is to be a 50-50 joint purchase with AstraZeneca plc, and that all Amylin's assets are to be placed in the Type II diabetes collaboration the two pharma companies established in January 2007.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter